Search Results for “ cardiovascular ” – Page 15 – media

Hengrui Pharmaceuticals’ Innovative Drug HRS-7249 Injection for the Treatment of Hyperlipidemia Approved for Clinical Trials

Recently, Hengrui Pharmaceuticals’ subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received a Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, which approved HRS-7249 Injection, a Class 1 new drug, to carry out clinical trials for the treatment of hyperlipidemia. Upon inquiry, no similar products have been approved for marketing at home and abroad for the time being. Hypertriglyceridemia (HTG) is a common type of dyslipidemia. Epidemiologic studies have shown that HTG is one of the risk factors for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis, and is clearly associated with overweight/obesity, insulin resistance/type 2 diabetes mellitus, non-alcoholic fatty liver disease, and chronic kidney disease. Currently, triglyceride-lowering drugs often used in clinical practice have limited reduction of triglycerides and have adverse effects such as hepatic and renal impairment, increased risk of atrial fibrillation, and decreased insulin sensitivity, and safer and more effective drugs are needed for ...
- Source: drugdu
- 98
- July 8, 2024
Pharmaconex

Organiser：Informa Markets Time： September 8-10, 2024 Address：El-Nasr Rd, Al Estad, Nasr City, Cairo Governorate Exhibition hall：Cairo International Convention Centre Product range: Vitamins, Hormones, Antipyretic Analgesics, Digestive System Medications, Anti-infective Drugs, Antiparasitic Drugs, Cardiovascular System Medications, Intermediates Pharmaceutical Packaging Materials: PVC/PVDC Laminates, PVC Rigid Sheets, PS Sheets, Anti-Counterfeiting Technology for Packaging, Label Sleeve Technology, Labeling Machines, Packaging Containers, Form-Fill-Seal Machines, Wrapping Machines, Paper Film Packaging Machinery, Bag Packaging Machines, etc. Infusion Equipment Production Lines, Dryers, Water Treatment Equipment, Refrigeration Compressors, Distillation Equipment, Sterilization Equipment, Tablet Presses, Coating Machines About Pharmaconex： Pharmaceutical Ingredients & Technology Exhibition in Cairo, Egypt, is the most renowned exhibition for pharmaceutical ingredients and technology in Egypt. Hosted by the renowned British exhibition company Informa Markets, with extensive experience and strong capabilities in organizing exhibitions, Pharmaconex plays a significant role in exploring the markets of Egypt and Africa.
- Source: drugdu
- 142
- July 5, 2024
First-Of-Its-Kind Integrated Heart Mapping to Prevent Damage Caused By Heart Attack

During and after a heart attack, the heart’s muscles suffer damage leading to the formation of scar tissue known as cardiac fibrosis. This scar tissue lacks the flexibility and contractility of healthy heart muscle, and its permanent presence can impair the heart’s pumping ability, potentially resulting in heart failure. Cardiac fibrosis is associated with all forms of heart disease, including those resulting from the overloading of the heart due to high blood pressure. Despite substantial investment in research seeking treatments to manage cardiac fibrosis, these efforts have largely been unsuccessful. There is a pressing need for innovative treatments that could halt or even reverse cardiac fibrosis, offering hope to millions affected. Scientists have now developed a first-of-its-kind integrated map of heart cells that sheds light on the process of cardiac fibrosis and could aid in preventing damage following a heart attack. This breakthrough achieved by researchers at the Victor Chang ...
- Source: drugdu
- 104
- July 3, 2024
Novartis China President and Managing Director Leo Lee Joins PhRMA China Executive Liaison Group

The Pharmaceutical Research and Manufacturers of America (PhRMA) China Office announced that Mr. Leo Lee, President and Managing Director of Novartis China, has joined the PhRMA China Executive Liaison Group. Mr. Lee, a long-time veteran of the biopharmaceutical industry who has held senior management positions in a number of multinational corporations and has extensive experience in strategy development and implementation, business development and operational management, joins PhRMA’s China Executive Liaison Group and expresses its confidence that Mr. Lee will bring invaluable experience to the group, as well as its appreciation to the member companies for their continued support of PhRMA. Novartis is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). About the PhRMA China Executive Liaison Group The China Executive Liaison Group (CELG) consists of the China General Managers of PhRMA member companies. As an important bridge between PhRMA China Office and member companies in China, the ...
- Source: drugdu
- 89
- July 2, 2024
IHI’s new funding round to include topics on CVD and arthritis

The initiative’s proposals aim to tackle current challenges in health research and innovation The Innovative Health Initiative (IHI) has launched a new call for proposals, which include topics on cardiovascular disease (CVD) and arthritis, as part of the total budget worth €96.5m to tackle challenges in health research and innovation. As part of the total budget, Horizon Europe, the EU’s research and innovation programme, has contributed €47.6m, while an additional €40.9m comes from the IHI’s industry members, as well as €8.1m from IHI contributing partners. Dr Niklas Blomberg, executive director, IHI, commented: “This call for proposals is an excellent opportunity to be part of ambitious projects tackling major challenges in health research and innovation.” The IHI aims to identify and create models, interventions and best practices to improve the management of CVD in Europe’s cities, covering healthcare delivery, individual lifestyle changes and the living environment. It will include five pilot ...
- Source: drugdu
- 97
- July 1, 2024
Scientists uncover new disease-driving mechanism to treat atheroschlerosis

Researchers from the University of Bristol have revealed a new disease-driving mechanism that could help treat the development of atherosclerosis. The new therapeutic, IMSET, is being developed by researchers at the Bristol Medical School: Translational Health Sciences (THS) and is being supported by funding through beLAB1407, one of Evotec’s global portfolio of BRIDGE partnerships. Affecting 42% of adults without heart disease, atherosclerosis is characterised by the build up of atherosclerotic plaques (fatty deposits) in the arteries, which can lead to heart attacks, strokes and peripheral arterial disease. When investigating how immune cells in the blood contribute to the creation of atherosclerotic plaques within the arteries, researchers found that these cells could exist in different forms, with particular types driving the development of the plaques. The discovery allowed researchers to identify a certain genetic target, known as IMSET, “which is a central regulator of their behaviour… [which] will allow us to ...
- Source: drugdu
- 62
- June 29, 2024
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease

The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank VinluanA Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
- Source: drugdu
- 100
- June 28, 2024
TOFIDENCE (BAT1806/BIIB800), a biosimilar developed by BIO-THERA with reference to Amero® (tolizumab), received marketing approval from the European Commission.

BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company is focused on developing a new generation of innovative drugs and biosimilars for the treatment of oncology, autoimmune diseases, cardiovascular diseases, ophthalmology and other major diseases that threaten human life or health. The Company’s partner, Bojian (NASDAQ: BIIB), recently received notification from the European Commission that it has granted marketing approval to BIO-THERA for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and other diseases. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in April 2024 for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. The European Commission’s approval of the marketing application for TOFIDENCE (BAT1806/BIIB800) ...
- Source: drugdu
- 67
- June 28, 2024
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease

The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank Vinluan A Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
- Source: drugdu
- 104
- June 27, 2024
Chiatai Tianqing’s Liraglutide Approved for Listing, Formally Entering the Field of Biological Drugs to Control Glucose

On June 25, Chiatai Tianqing received the Certificate of Drug Registration approved by the State Drug Administration, and the company’s liraglutide injection was approved to be listed in the market, which is used for controlling blood glucose in adult patients with type 2 diabetes mellitus. This is the ninth new product (including new indications) approved by Chiatai Tianqing since this year. The approval of this product also marks Chiatai Tianqing’s formal entry into the field of biopharmaceutical glycemic control. Liraglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) with 97% homology to natural GLP-1, an endogenous enteric insulinotropic hormone that enhances glucose-dependent insulin secretion from pancreatic β-cells. In addition to pancreatic islet cells, GLP-1 receptors are widely present in gastrointestinal, lung, brain, kidney, cardiovascular system and other organs and tissues. Liraglutide prolongs the half-life of GLP-1 on the basis of retaining the physiological action characteristics of GLP-1, and needs to ...
- Source: drugdu
- 87
- June 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.